Pfizer's investigational trispecific antibody tilrekimig (PF-07275315) met its primary endpoint in a Phase 2 trial, with 62.5% of biologic-naïve adults with moderate-to-severe atopic dermatitis achieving EASI-75 at Week 16 on 450 mg every two weeks, versus 19.9% on placebo (p=0.0008). The detailed data were presented in an oral session at the 35th EADV Congress in Vienna on October 1, 2026.

Tilrekimig is a potential first-in-class trispecific antibody that binds interleukin-4, interleukin-13 and thymic stromal lymphopoietin with high affinity, blocking both upstream and downstream drivers of type 2 inflammation. Its roughly 37-day half-life is designed to support monthly administration.

What did the dose-ranging stage show?

Stage 2 of the randomized, double-blind, placebo-controlled trial tested three once-monthly doses:

• 400 mg Q4W: 58.5% reached EASI-75, an absolute improvement of 49.4% over placebo
• 200 mg Q4W: 61.0% reached EASI-75, an absolute improvement of 51.9%
• 50 mg Q4W: 47.8% reached EASI-75, an absolute improvement of 38.7%

All comparisons cleared p<0.003 against a 9.1% placebo response. On the key secondary endpoint of vIGA 0/1 (clear or almost clear skin with ≥2-point improvement), Stage 1 patients on 450 mg Q2W achieved 30.3% versus 11.8% for placebo (p=0.0251). Across Stage 2 Q4W groups, 26%–27% achieved vIGA 0/1 against 0% for placebo (all p<0.006).

Itch data were exploratory. A ≥4-point reduction on the weekly Peak Pruritus NRS was reached by 42.5% of patients on 400 mg Q4W and 50.8% on 200 mg Q4W, versus 7.2% on placebo — treatment differences of 35.3% and 43.6%.

How did the safety profile look?

Tilrekimig was well tolerated, with no dose-dependent safety signals and no related serious adverse events in either stage. Treatment-emergent adverse event rates were comparable between active arms and placebo:

• Stage 1: 46.7% (450 mg Q2W) versus 28.9% (placebo)
• Stage 2: 42.2%, 47.7% and 47.8% across the 400 mg, 200 mg and 50 mg Q4W arms versus 52.2% (placebo)

At doses up to 400 mg Q4W, observed frequencies of conjunctivitis and injection-site reactions were lower than reported rates with IL-4 receptor alpha inhibitors and comparable to placebo.

How does this fit the AD treatment pipeline?

Eric Simpson, M.D., M.C.R., of Oregon Health & Science University's dermatology department, framed the unmet need: "A substantial proportion of patients still live with persistent itch and extensive skin involvement. The Week 16 results presented today are meaningful at this stage of development, with tilrekimig's tolerability profile supporting continued study in a larger patient population."

Pfizer has already dosed patients in three Phase 3 studies — two in atopic dermatitis, including one with dupilumab as an active comparator, and one in asthma — plus a Phase 2b/3 study in COPD.

Michael Vincent, M.D., Ph.D., Pfizer's Chief Inflammation & Immunology Officer, said the findings "validate this multi-pathway, trispecific approach and suggest that tilrekimig has the potential to raise the bar beyond current standard-of-care biologics."

The tilrekimig presentation sits within a broader Pfizer portfolio at EADV — more than 30 accepted abstracts across atopic dermatitis, alopecia areata and nonsegmental vitiligo, including a final integrated safety analysis of 3,850 abrocitinib patients with up to 6.5 years of exposure and Phase 3 LITFULO data in vitiligo and alopecia areata. The head-to-head Phase 3 comparison against dupilumab will define whether the trispecific mechanism's theoretical durability advantage translates into practice.